Brought to you by 
Wyeth-Ayerst to co-develop Scios's Fiblast growth factor
28 Oct 1999
Executive Summary
Scios signed up the Wyeth-Ayerst unit of American Home Products to co-develop and jointly market its Phase I fibroblast growth factor Fiblast (trafermin) for treating stroke, peripheral vascular disorders and possibly congestive heart failure.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Wyeth-Ayerst to co-develop Scios's Fiblast growth factor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice